{"id":8871,"date":"2024-04-17T14:49:31","date_gmt":"2024-04-17T21:49:31","guid":{"rendered":"https:\/\/www.jdrf.org\/pacificnorthwest\/?p=7824"},"modified":"2025-12-01T20:21:53","modified_gmt":"2025-12-01T20:21:53","slug":"more-clinical-trial-news-in-the-pacific-northwest","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/","title":{"rendered":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST!"},"content":{"rendered":"<p>In this update, we would like to highlight important studies currently enrolling at the research universities in our chapter, the University of Washington (UW) and Oregon Health &amp; Science University (OHSU).<\/p>\n<p>&nbsp;<\/p>\n<p><strong><u>REMODEL T1D (RT1D) STUDY<\/u><\/strong><\/p>\n<p>In our last update, we shared that one area of focus in current Type 1 Diabetes (T1D) research is looking to see if drugs that have proven beneficial in Type 2 Diabetes (T2D) will have similar benefits for people with T1D.\u00a0 The GLP-1 class of medications is one such area of focus, as we discussed in detail in our <a href=\"https:\/\/www.jdrf.org\/pacificnorthwest\/2024\/03\/01\/new-weight-loss-and-improved-glucose-management-study-at-rainier-clinical-research-center-for-people-living-with-t1d\/\">March Update<\/a>.<\/p>\n<p>GLP-1 agonists have been beneficial in T2D for their improvement of glycemic control and weight loss, as well as for their protective effects on the heart and kidney.<\/p>\n<p>REMODEL T1D is looking at the potential benefits of the GLP-1 agonist, Semaglutide, on kidney function in people with abnormal kidney function due to T1D.\u00a0 A secondary objective is to study the glycemic effects of Semaglutide in people with T1D.\u00a0 This study is being conducted at UW in Seattle.<\/p>\n<p>The study will last 26 weeks, including a gradual titration of study medications to maximum target dose over 12 weeks, followed by evaluation of the effect of Semaglutide on the kidney. Evaluation will include kidney MRI, urine testing and blood testing.<\/p>\n<p>You may be eligible for this study if you:<\/p>\n<ul>\n<li>Are 18 years of age or older<\/li>\n<li>Have been diagnosed with T1D for at least 5 years<\/li>\n<li>Have abnormal kidney function due to T1D<\/li>\n<li>Are on stable doses of medications for blood pressure and cholesterol<\/li>\n<\/ul>\n<p>If interested, please contact: Evelin Jones, <a href=\"blank\">evelinj@Nephrology.washington.edu<\/a> \u00a0<strong><em>or<\/em><\/strong> Dori Khakpour, <a href=\"blank\">dorik@uw.edu<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong><u>MULTI-SITE T1D CLOSED LOOP STUDY<\/u><\/strong><\/p>\n<p>This study is investigating a new investigational closed loop system, called iPancreas, which can detect exercise and missed meal boluses and adjust insulin dosing accordingly.\u00a0 The system uses Fiasp insulin, a faster-acting version of Novolog.\u00a0 The study is being conducted at OHSU, with an additional site at UW in Seattle.<\/p>\n<p>During the course of the study, you will complete two visits. For one visit, you will use the study device with Fiasp insulin starting with a 6 hour visit on campus, followed by you using the system at home for 7 days. The other visit will require you to use your t:slim X2 pump with Control IQ with your own insulin for 7 days at home.<\/p>\n<p>You may be eligible for this study if you:<\/p>\n<ul>\n<li>Are 18 years of age or older<\/li>\n<li>Have been using the t:slim X2 pump with Control IQ active for at least 12 weeks<\/li>\n<li>Have a HbA1c or GMI 7.5% or higher<\/li>\n<\/ul>\n<p>If interested, please contact:\u00a0 Deborah Branigan, <a href=\"blank\">oregonapc@ohsu.edu<\/a>, 503-418-9070 for OHSU or Rosanna Holod, <a href=\"blank\">rambre@uw.edu<\/a> or Dori Khakpour, <a href=\"blank\">dorik@uw.edu<\/a> for UW.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><u>DAILY DOSE SMART SNACK STUDY<\/u><\/strong><\/p>\n<p>OHSU also is testing a smart phone app, called Daily Dose.\u00a0 By integrating with the Dexcom CGM, the app will predict overnight hypoglycemia and suggest an appropriate personalized bedtime snack.\u00a0 The goal of this study is to test how well the Daily Dose app prevents nighttime hypoglycemia in people using multiple daily injections (MDIs).<\/p>\n<p>Participation in the study will consist of 6 clinic and 6 phone visits over approximately 12 weeks. Some visits can be virtual.\u00a0 During the study, you will be asked to wear a Dexcom G6 CGM (provided).\u00a0 You also will be asked to wear an Apple watch (provided during the study period) at night and complete a survey about sleep quality each week.\u00a0 You will weigh yourself weekly.\u00a0 The snacks recommended by the Daily Dose app will be provided by the study.<\/p>\n<p>You may be eligible for this study if you:<\/p>\n<ul>\n<li>Are 18 years of age or older<\/li>\n<li>Have been diagnosed with T1D for at least one year<\/li>\n<li>Are using multiple daily injection therapy<\/li>\n<li>Have an HbA1c &lt;10% at time of screening<\/li>\n<li>Are currently using a glucose sensor with at least 2 episodes of overnight low glucose of less than 70 mg\/dl for at least 10 minutes between 10pm and 6am in last 30 days<\/li>\n<\/ul>\n<p>If interested, please contact:\u00a0 Deborah Branigan, <a href=\"blank\">oregonapc@ohsu.edu<\/a>, 503-418-9070.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In this update, we would like to highlight important studies currently enrolling at the research universities in our chapter, the University of Washington (UW) and Oregon Health &amp; Science University (OHSU). &nbsp; REMODEL T1D (RT1D) STUDY In our last update,&hellip;<\/p>\n","protected":false},"author":1317,"featured_media":8872,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":6,"footnotes":"","bt1d_storytelling_post":false,"bt1d_storytelling_more_posts":[]},"topics":[31],"class_list":["post-8871","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","jdrf_topic-clinical-trials"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter\" \/>\n<meta property=\"og:description\" content=\"In this update, we would like to highlight important studies currently enrolling at the research universities in our chapter, the University of Washington (UW) and Oregon Health &amp; Science University (OHSU). &nbsp; REMODEL T1D (RT1D) STUDY In our last update,&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Northwest Chapter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-17T21:49:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T20:21:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Breakthrough T1D Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Breakthrough T1D Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\"},\"author\":{\"name\":\"Breakthrough T1D Author\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6\"},\"headline\":\"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST!\",\"datePublished\":\"2024-04-17T21:49:31+00:00\",\"dateModified\":\"2025-12-01T20:21:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\"},\"wordCount\":695,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\",\"name\":\"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter\",\"isPartOf\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg\",\"datePublished\":\"2024-04-17T21:49:31+00:00\",\"dateModified\":\"2025-12-01T20:21:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg\",\"contentUrl\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/\",\"name\":\"Greater Northwest Chapter\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png\",\"contentUrl\":\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/breakthrought1dHQ\",\"https:\/\/x.com\/breakthrought1d\",\"https:\/\/www.youtube.com\/@breakthrought1d\",\"https:\/\/www.instagram.com\/breakthrought1d\/\",\"https:\/\/www.tiktok.com\/@breakthrought1dhq\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6\",\"name\":\"Breakthrough T1D Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"caption\":\"Breakthrough T1D Author\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/","og_locale":"en_US","og_type":"article","og_title":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter","og_description":"In this update, we would like to highlight important studies currently enrolling at the research universities in our chapter, the University of Washington (UW) and Oregon Health &amp; Science University (OHSU). &nbsp; REMODEL T1D (RT1D) STUDY In our last update,&hellip;","og_url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/","og_site_name":"Greater Northwest Chapter","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_published_time":"2024-04-17T21:49:31+00:00","article_modified_time":"2025-12-01T20:21:53+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg","type":"image\/jpeg"}],"author":"Breakthrough T1D Author","twitter_card":"summary_large_image","twitter_creator":"@breakthrought1d","twitter_site":"@breakthrought1d","twitter_misc":{"Written by":"Breakthrough T1D Author","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#article","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/"},"author":{"name":"Breakthrough T1D Author","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6"},"headline":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST!","datePublished":"2024-04-17T21:49:31+00:00","dateModified":"2025-12-01T20:21:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/"},"wordCount":695,"commentCount":0,"publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage"},"thumbnailUrl":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/","name":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST! - Greater Northwest Chapter","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage"},"thumbnailUrl":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg","datePublished":"2024-04-17T21:49:31+00:00","dateModified":"2025-12-01T20:21:53+00:00","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#primaryimage","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg","contentUrl":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-content\/uploads\/sites\/171\/2024\/04\/louis-reed-pwcKF7L4-no-unsplash-scaled-1.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/04\/17\/more-clinical-trial-news-in-the-pacific-northwest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/"},{"@type":"ListItem","position":2,"name":"MORE CLINICAL TRIAL NEWS IN THE PACIFIC NORTHWEST!"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","name":"Greater Northwest Chapter","description":"","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]},{"@type":"Person","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6","name":"Breakthrough T1D Author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","caption":"Breakthrough T1D Author"}}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/8871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/users\/1317"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/comments?post=8871"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/8871\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/media\/8872"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/media?parent=8871"}],"wp:term":[{"taxonomy":"jdrf_topic","embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/topics?post=8871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}